Cargando…
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI
Clostridium difficile infection (CDI) is an enteric bacterial disease that is increasing in prevalence worldwide. C. difficile capitalizes on gut inflammation and microbiome dysbiosis to establish infection, with symptoms ranging from watery diarrhea to toxic megacolon. We reported that the safe-in-...
Autores principales: | Garland, Megan, Hryckowian, Andrew J., Tholen, Martina, Oresic Bender, Kristina, Van Treuren, William W., Loscher, Sebastian, Sonnenburg, Justin L., Bogyo, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263476/ https://www.ncbi.nlm.nih.gov/pubmed/32483557 http://dx.doi.org/10.1016/j.xcrm.2020.100005 |
Ejemplares similares
-
Microbiota Accessible Carbohydrates Suppress Clostridium difficile Infection in a Murine Model
por: Hryckowian, Andrew J, et al.
Publicado: (2018) -
Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI
por: Castro, Iván, et al.
Publicado: (2019) -
Antibacterial Activity of Ebselen
por: Maślanka, Marta, et al.
Publicado: (2023) -
Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012) -
The Potential Use of Ebselen in Treatment-Resistant Depression
por: Ramli, Fitri Fareez, et al.
Publicado: (2022)